2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1074

The Risk of Obstetric Complications and the Effects of Treatment in Women with Low Titer and Medium-High Titer Anti-Phospholipid Antibodies

Antiphospholipid Syndrome - Poster I

9:00AM-11:00AM: Abstract Number: 1784

The Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Lupus Erythematosus: A Population-Based Study

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1749

The Role of Mucosal-Associated Invariant T (MAIT) Cells in Lupus Dermatitis

Systemic Lupus Erythematosus – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 1377

The Role of Muscle MRI in Detecting a Flare-up of Juvenile Dermatomyositis

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1574

The Role of Shelterin Deficiency in the Senescence in T Cells of Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 1830

The Role of Tripartite Motif-Containing 21 in Interferon Signature of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1361

The Role of Von Willebrand Factor Antigen As a Disease Biomarker in the Clinical Assessment of Children with Juvenile Dermatomyositis

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1909

The Transcription Factor Fra2 Is Playing a Key Role in Treg Development and Autoimmunity

T Cell Biology and Targets in Autoimmune Disease - Poster Session I

9:00AM-11:00AM: Abstract Number: 1186

The Use of Clinical Mucosal Manifestations to Differentiate Patients with Lupus and Dermatomyositis: Transversal, Retrospective and Analytical Study of 116 Patients

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1290

The Usefulness of Volumetric Parameters of FDG PET/CT for Reflecting Disease Activity in Polymyositis/Dermatomyositis Patients

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1139

The Virtual Rheumatology Clinic: Virtual Patients for Resident Education in Rheumatology

Education - Poster

9:00AM-11:00AM: Abstract Number: 1447

Therapeutic Blockade of Interleukin-6 Trans-Signalling Restores Vascular Function in Murine Collagen Induced Arthritis

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1448

Therapeutic Role of a Novel Histone Deacetylase 6 Inhibitor, CKD-M808, in Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1905

Therapeutic Targeting of JAK/STAT Pathway Inhibits Follicular Helper T Cell Maturation and Function

T Cell Biology and Targets in Autoimmune Disease - Poster Session I

9:00AM-11:00AM: Abstract Number: 1175

Thirty Day Readmission Rates for Patients Diagnosed with Systemic Lupus Erythematosus: Analysis at a Tertiary Care Center

Epidemiology and Public Health - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].